Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13753721 | 0.74 | PTPRC (0.41) | KMT2AMAPTPOLBSMN1; SMN2PTPRC | |
| SCHEMBL695137 | 0.73 | KMT2A (0.41) | CYP19A1KMT2APOLBCNR2NFATC1 | |
| SCHEMBL11537268 | 0.71 | PTPRC (0.39) | KMT2AMAPTPTPRCNPSR1 | |
| SCHEMBL700564 | 0.71 | PTPRC (0.45) | KMT2AMAPTPTPRCNPSR1 | |
| SCHEMBL693608 | 0.71 | PTPRC (0.45) | KMT2AMAPTPTPRCNPSR1 | |
| SCHEMBL2027835 | 0.70 | CA2 (0.60) | CYP19A1KMT2AMAPT | |
| SCHEMBL2025801 | 0.69 | CYP2C19 (0.68) | CYP19A1KMT2AMAPTPOLBCYP1A2 | |
| SCHEMBL14445423 | 0.69 | RPS6KB2 (0.45) | KMT2AMAPTPTPRCNPSR1 | |
| SCHEMBL31671451 | 0.69 | CYP2C19 (0.68) | CYP19A1KMT2AMAPTPOLBCYP1A2 | |
| SCHEMBL16465028 | 0.67 | POLB (0.41) | KMT2AMAPTPOLBSMN1; SMN2PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741914-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2421845-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LAB (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20120100104-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100104-A1 | Antiviral Compounds And Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | XDH 732/4885CYP19A1 4092/4885KMT2A 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.